Bank of New York Mellon’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43.8M | Buy |
394,044
+100,746
| +34% | +$9.11M | 0.01% | 1153 |
|
|
2026
Q1 | $25.5M | Sell |
293,298
-7,782
| -3% | -$757K | ﹤0.01% | 1406 |
|
|
2025
Q4 | $32.2M | Buy |
301,080
+118,715
| +65% | +$12.6M | 0.01% | 1265 |
|
|
2025
Q3 | $18.4M | Sell |
182,365
-1,744
| -0.9% | -$162K | ﹤0.01% | 1593 |
|
|
2025
Q2 | $11.6M | Buy |
184,109
+37,524
| +26% | +$2.3M | ﹤0.01% | 1821 |
|
|
2025
Q1 | $7.76M | Sell |
146,585
-1,661
| -1% | -$92.2K | ﹤0.01% | 1991 |
|
|
2024
Q4 | $8.3M | Sell |
148,246
-680
| -0.5% | -$37.6K | ﹤0.01% | 2019 |
|
|
2024
Q3 | $7.8M | Sell |
148,926
-42,945
| -22% | -$2.06M | ﹤0.01% | 2066 |
|
|
2024
Q2 | $7.88M | Buy |
191,871
+24,033
| +14% | +$959K | ﹤0.01% | 2090 |
|
|
2024
Q1 | $7.27M | Sell |
167,838
-12,384
| -7% | -$542K | ﹤0.01% | 2139 |
|
|
2023
Q4 | $8.28M | Buy |
180,222
+2,846
| +2% | +$89.8K | ﹤0.01% | 2079 |
|
|
2023
Q3 | $4.07M | Sell |
177,376
-10,420
| -6% | -$233K | ﹤0.01% | 2424 |
|
|
2023
Q2 | $3.1M | Buy |
187,796
+161,070
| +603% | +$2.91M | ﹤0.01% | 2594 |
|
|
2023
Q1 | $477K | Sell |
26,726
-5,557
| -17% | -$140K | ﹤0.01% | 3512 |
|
|
2022
Q4 | $940K | Sell |
32,283
-7,625
| -19% | -$196K | ﹤0.01% | 3217 |
|
|
2022
Q3 | $978K | Buy |
39,908
+18,413
| +86% | +$342K | ﹤0.01% | 3213 |
|
|
2022
Q2 | $89K | Sell |
21,495
-130,854
| -86% | -$716K | ﹤0.01% | 4250 |
|
|
2022
Q1 | $1.76M | Sell |
152,349
-4,569
| -3% | -$40.1K | ﹤0.01% | 3010 |
|
|
2021
Q4 | $1.57M | Buy |
156,918
+495
| +0.3% | +$5.56K | ﹤0.01% | 3137 |
|
|
2021
Q3 | $2.04M | Buy |
156,423
+16,391
| +12% | +$250K | ﹤0.01% | 2961 |
|
|
2021
Q2 | $2.74M | Buy |
140,032
+3,878
| +3% | +$80.5K | ﹤0.01% | 2805 |
|
|
2021
Q1 | $2.9M | Buy |
136,154
+5,732
| +4% | +$166K | ﹤0.01% | 2714 |
|
|
2020
Q4 | $3.88M | Buy |
130,422
+5,734
| +5% | +$146K | ﹤0.01% | 2479 |
|
|
2020
Q3 | $2.7M | Sell |
124,688
-1,618
| -1% | -$37.1K | ﹤0.01% | 2506 |
|
|
2020
Q2 | $2.82M | Buy |
126,306
+10,476
| +9% | +$204K | ﹤0.01% | 2490 |
|
|
2020
Q1 | $1.76M | Buy |
115,830
+5,890
| +5% | +$105K | ﹤0.01% | 2618 |
|
|
2019
Q4 | $2.52M | Buy |
109,940
+24,510
| +29% | +$544K | ﹤0.01% | 2680 |
|
|
2019
Q3 | $1.84M | Sell |
85,430
-629
| -0.7% | -$13.5K | ﹤0.01% | 2795 |
|
|
2019
Q2 | $1.89M | Buy |
86,059
+16,507
| +24% | +$417K | ﹤0.01% | 2822 |
|
|
2019
Q1 | $1.91M | Buy |
69,552
+2,464
| +4% | +$70.8K | ﹤0.01% | 2796 |
|
|
2018
Q4 | $1.8M | Buy |
67,088
+6,814
| +11% | +$188K | ﹤0.01% | 2775 |
|
|
2018
Q3 | $1.76M | Buy |
60,274
+22,481
| +59% | +$710K | ﹤0.01% | 2923 |
|
|
2018
Q2 | $1.18M | Buy |
37,793
+13,462
| +55% | +$368K | ﹤0.01% | 3161 |
|
|
2018
Q1 | $485K | Buy |
24,331
+6,323
| +35% | +$168K | ﹤0.01% | 3605 |
|
|
2017
Q4 | $523K | Buy |
+18,008
| New | +$476K | ﹤0.01% | 3603 |
|
Other funds holding RYTM
N
Bank of New York Mellon's RYTM Position: Q2 2026 in Review
Bank of New York Mellon increased its Rhythm Pharmaceuticals (RYTM) stake by 34% in Q2 2026, buying an estimated $9.11M and bringing the position to 394,044 shares worth $43.8M. The position accounts for 0.01% of the portfolio, ranked #1153.
Bank of New York Mellon first reported a position in RYTM in Q4 2017 and has held it in 35 quarters since. 104 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.
- Bank of New York Mellon held 394,044 shares of Rhythm Pharmaceuticals worth $43.8M as of Q2 2026.
- Bank of New York Mellon bought 100,746 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $9.11M.
- Rhythm Pharmaceuticals made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1153 holding.
- Bank of New York Mellon first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- 104 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.